Please assess the completion status of the following clinical trial:

Trial Title: Europe-Africa Research Network for Evaluation of Second-line Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously documented HIV infection on at least one standard antibody-based test~* Age 12 years and above~* Taking 2NRTI + NNRTI-based regimen continuously for at least 12 months~* Naive to protease inhibitor therapy~* Good adherence to ART in the 12 weeks prior to screening defined as missing medication on no more than 3 days in the prior month~* Clinically stable and receiving treatment for any known opportunistic infections~* HIV treatment failure defined by one or more of clinical, immunological or virological criteria defined in the protocol, including VL and CD4 at screening visit~* Willing and able to give informed consent~* Able to attend for regular study follow up visits~Exclusion Criteria:~* Any major clinical contra-indications to the use of bPI, the NRTIs that are available to be selected for a second-line regimen or raltegravir~* Known Hepatitis B carrier (Hepatitis B surface antigen positive if tested)~* Requires concomitant medication with known major interactions with study drugs for which drug substitutions or dose alterations are not available or acceptable~* Women who are currently pregnant or breastfeeding~* Current participation in another clinical trial involving a treatment intervention (may be permitted in some circumstances, but must be discussed with MRC CTU)~* Life expectancy of less than one month in the opinion of the treating physician

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bPI + 2NRTIs (Type: ACTIVE_COMPARATOR): None
- bPI + raltegravir (Type: EXPERIMENTAL): None
- bPI monotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).